SI-BONE, INC. (SIBN) Current Ratio
- Current ratio · latest quarter: Value 9.15×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 9.15× | Current assets / current liabilities. $219.91M ÷ $24.04M ≈ 9.15× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 219.91M USD | Assets, Current |
| Current obligations | 24.04M USD | Liabilities, Current |
| Cash and equivalents | 33.13M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 31.18M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 38.39M USD | Inventory, Net |
| Payables | 8.54M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $219.91M | $24.04M | $33.13M | (m) | $31.18M | $38.39M | $8.54M | (m) | 9.15× |
| 2026-03-31 | $214.72M | $21.49M | $33.53M | (m) | $30.96M | $35.53M | $6.76M | (m) | 9.99× |
| 2025-12-31 | $216.12M | $25.28M | $42.24M | (m) | $29.91M | $33.90M | $4.63M | (m) | 8.55× |
| 2025-09-30 | $210.78M | $26.44M | $26.49M | (m) | $26.53M | $35.73M | $7.72M | (m) | 7.97× |
| 2025-06-30 | $207.45M | $24.75M | $34.15M | (m) | $24.37M | $34.24M | $7.50M | (m) | 8.38× |
| 2025-03-31 | $204.20M | $23.95M | $41.19M | (m) | $26.70M | $30.38M | $7.71M | (m) | 8.53× |
| 2024-12-31 | $207.78M | $27.13M | $34.95M | (m) | $27.46M | $27.07M | $6.49M | (m) | 7.66× |
| 2024-09-30 | $203.70M | $24.68M | $30.23M | (m) | $24.91M | $25.52M | $7.32M | (m) | 8.25× |
| 2024-06-30 | $202.33M | $22.06M | $25.58M | (m) | $24.80M | $23.23M | $7.18M | (m) | 9.17× |
| 2024-03-31 | $203.63M | $20.86M | $32.04M | (m) | $22.11M | $21.05M | $7.66M | (m) | 9.76× |
| 2023-12-31 | $211.39M | $23.46M | $33.27M | (m) | $21.95M | $20.25M | $4.59M | (m) | 9.01× |
| 2023-09-30 | $211.02M | $19.37M | $53.49M | (m) | $19.99M | $22.34M | $4.42M | (m) | 10.89× |
| 2023-06-30 | $212.53M | $18.20M | $110.81M | (m) | $20.42M | $20.55M | $6.16M | (m) | 11.68× |
| 2023-03-31 | $128.40M | $16.63M | $22.97M | (m) | $22.60M | $17.79M | $5.33M | (m) | 7.72× |
| 2022-12-31 | $137.61M | $21.18M | $20.72M | (m) | $20.67M | $17.28M | $6.28M | (m) | 6.50× |
| 2022-09-30 | $139.18M | $18.56M | $26.30M | (m) | $16.45M | $16.85M | $4.61M | $1.46M | 7.50× |
| 2022-06-30 | $148.34M | $16.67M | $24.32M | (m) | $15.12M | $16.48M | $5.14M | $0.00 | 8.90× |
| 2022-03-31 | $161.26M | $15.45M | $27.33M | (m) | $12.68M | $14.71M | $5.00M | (m) | 10.44× |
| 2021-12-31 | $175.87M | $16.89M | $63.42M | $83.56M | $14.25M | $11.50M | $3.20M | (m) | 10.41× |
| 2021-09-30 | $185.65M | $14.56M | $59.86M | $100.99M | $12.62M | $10.25M | $4.14M | (m) | 12.75× |
| 2021-06-30 | $199.11M | $12.62M | $48.13M | $128.51M | $11.89M | $8.15M | $3.92M | (m) | 15.77× |
| 2021-03-31 | $208.11M | $13.71M | $37.36M | $147.69M | $13.09M | $7.41M | $5.18M | (m) | 15.18× |
| 2020-12-31 | $218.24M | $13.47M | $53.58M | $142.85M | $13.61M | $5.63M | $3.27M | (m) | 16.20× |
| 2020-09-30 | $149.52M | $11.82M | $56.00M | $76.02M | $11.42M | $5.07M | $3.10M | $0.00 | 12.65× |
| 2020-06-30 | $154.53M | $11.73M | $66.17M | $71.50M | $10.26M | $4.97M | $2.46M | $0.00 | 13.18× |
| 2020-03-31 | $161.96M | $20.59M | $67.57M | $77.37M | $9.36M | $5.73M | $2.58M | $8.73M | 7.87× |
| 2019-12-31 | $111.46M | $18.77M | $10.44M | $81.34M | $11.72M | $5.45M | $2.81M | $4.36M | 5.94× |
| 2019-09-30 | $112.71M | $12.83M | $12.61M | $83.61M | $9.92M | $4.95M | $2.62M | (m) | 8.78× |
| 2019-06-30 | $119.02M | $9.92M | $11.50M | $91.78M | $9.40M | $4.44M | $2.45M | (m) | 12.00× |
| 2019-03-31 | $129.40M | $9.91M | $12.56M | (m) | $8.41M | $3.52M | $2.81M | (m) | 13.06× |
| 2018-12-31 | $136.04M | $9.01M | $25.12M | $97.10M | $8.49M | $3.34M | $2.15M | $0.00 | 15.11× |
| 2018-09-30 | $24.86M | $8.94M | $14.00M | (m) | $7.09M | $3.03M | $1.79M | (m) | 2.78× |
| 2017-12-31 | $33.63M | $7.54M | $22.41M | (m) | $7.42M | $2.55M | $1.81M | (m) | 4.46× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |